Disclosures The data in this paper were presented in part at the 16th European Meeting on Hypertension, 12–15 June 2006, Madrid, Spain and ISPOR 9th Annual European Congress, 28–31 October 2006, Copenhagen, Denmark. Development of this manuscript was sponsored by Novartis Pharma AG. Joyce Cramer does not have a direct or indirect financial interest in Novartis Pharma AG, nor has she received an honorarium to author this manuscript. Ágnes Benedict and Noémi Muszbek are employees of United BioSource. As a research organisation, United BioSource conducted the original literature review upon which this article is based. United BioSource has undertaken similar projects for other pharmaceutical companies. Abdulkadir Keskinaslan and Zeba M. Khan are directly employed by Novartis Pharma AG and Novartis Pharmaceuticals Corporation respectively. Editorial support was provided by Rx Communications Limited.
The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review
Article first published online: 5 NOV 2007
International Journal of Clinical Practice
Volume 62, Issue 1, pages 76–87, January 2008
How to Cite
Cramer, J. A., Benedict, Á., Muszbek, N., Keskinaslan, A. and Khan, Z. M. (2008), The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review. International Journal of Clinical Practice, 62: 76–87. doi: 10.1111/j.1742-1241.2007.01630.x
Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
- Issue published online: 5 NOV 2007
- Article first published online: 5 NOV 2007
- Paper received June 2007, accepted September 2007
- 3American Heart Association. Heart Disease and Stroke Statistics – 2006 Update. Dallas, TX: American Heart Association.
- 10World Health Organization (WHO). Adherence to Long Term Therapies: Evidence for Action. Geneva: WHO, 2003.
- 12Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev 2004; CD004371., , et al.
- 13Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; CD004804., , .
- 14Healthcare Cost, Quality and Outcomes: ISPOR Book of Terms. Lawrenceville, NJ: ISPOR, 2003., , et al. (eds).
- 15ISPOR Medication Compliance and Persistence Special Interest Group (MCP): Accomplishments. International Society for Pharmacoeconomics & Outcomes Research (ISPOR). http://www.ispor.org/sigs/mcp_accomplishments.asp#definition (accessed June 2007).
- 20Patient adherence and persistence with antihypertensive therapy: one-versus two-pill combinations. J Hypertens 2005; 23 (Suppl. 2): S236., , et al.
- 22Why objective monitoring of compliance is important in the management of hypertension. J Clin Hypertens (Greenwich) 2000; 2: 258–62., , , , .
- 28Compliance with statins in primary care. Pharm J 2004; 272: 23–6., , et al.